Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768962 | 0.83 | HIF1A (0.58) | RAB9ANPC1ALDH1A1KMT2AHIF1A | |
| SCHEMBL2769249 | 0.82 | HIF1A (0.60) | RAB9ANPC1ALDH1A1KMT2AHIF1A | |
| SCHEMBL2770378 | 0.78 | HIF1A (0.51) | RAB9ANPC1HTR2ADRD3KMT2A | |
| SCHEMBL2768960 | 0.75 | P2RX1 (0.41) | RAB9ANPC1ALDH1A1KMT2AHIF1A | |
| SCHEMBL2767341 | 0.73 | SMN1; SMN2 (0.42) | RAB9ANPC1ALDH1A1KMT2AHIF1A | |
| SCHEMBL2769812 | 0.73 | TDP1 (0.45) | RAB9AALDH1A1KMT2AHIF1A | |
| SCHEMBL2769297 | 0.73 | NPC1 (0.45) | RAB9ANPC1ALDH1A1KMT2AHIF1A | |
| SCHEMBL4347655 | 0.71 | MEN1 (0.47) | RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL2770589 | 0.71 | MAPT (0.53) | RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL2768643 | 0.70 | HIF1A (0.49) | RAB9ANPC1ALDH1A1KMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881967-B1 | SUBSTITUTED BENZO(D)ISOXAZOL-3-YL AMINE COMPOUNDS AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | RAB9A 3127/4885NPC1 2230/4885HTR2A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.